Any current/future capex/capital investment/strategic investment?

Ongoing capital investments are focused on Injectables, Insulin, Monoclonal Antibodies (MABs), and GLP-1 segments, continuing as per guidance (Page 16). CapEx for FY26 Q3 was about INR 80 crore, with nine-month CapEx around INR 200 crore, targeting Insulin, GLP-1, and Injectable projects (Page 5). The 3-year CapEx guidance remains around INR 200-250 crore per annum, totaling approximately INR 750 crore for FY26-FY28 (Pages 5 and 6). Investment front-loaded to capitalize on strategic opportunities in Injectable Insulin and GLP segments (Page 6). New manufacturing Unit 3 at Swiss facility to be

Future growth expectations in sales/revenue/volumes?

Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands. DBF segment targets a 37% operating margin this year and 39%+ EBITDA margin next year. Significant market share gains in the RHI insulin cartridge segment: from 8% at acquisition to 25-26% by Dec-Jan, with further growth expected in the RHI plus Glargine segment over the next 3 years. International business delivered 45% revenue growth in Q3, with strong visibility for FY27 revenue between INR 550-600 crores.

Future growth expectations in earnings/operating earnings/profits/EPS?

Eris Lifesciences forecasts 12% revenue growth in Domestic Branded Formulations (DBF) for FY26 with a 37% operating margin. Consolidated Q3 revenue grew 11% YoY to INR 807 crore with a consolidated margin expansion of 80 bps to 36% YTD. Profit After Tax (PAT) growth from operations was about 39% in Q3. International business is expected to reach INR 550-600 crore in revenue in FY27, marking a breakout year. The CDMO revenue is expected to be INR 125-160 crore next year, with full commercialization of the INR 1,000 crore order book spread over three years. FY26 EBITDA margin for DBF expected ab

Current/ Expected Orderbook/ Pending Orders?

The current CDMO order book stands at an annualized size of INR 1,000 crore as of Q3FY26. This INR 1,000 crore order book is additional to the existing base business, primarily from the Swiss facility. The full commercialization and execution of this INR 1,000 crore order book is expected to take about three years. For the next year (FY27), the company expects CDMO revenues of INR 125-160 crore. The company has strong visibility of FY27 as a breakout year for international revenues, targeting INR 550-600 crore. Capacity-wise, Swiss operates two facilities currently, sufficient for FY27; a thir

Any current/future new fundraising through debt or equity?

No specific mention of new fundraising through debt or equity in the current quarter. The company disclosed that CapEx guidance for the next 3 years remains unchanged at around INR 750 crore. They are focused on managing and reducing net debt to reach a target net debt to EBITDA ratio of 1.5x by the end of the calendar year. Debt repayment schedules remain consistent with the previous quarter; no changes reported. Capital investments continue primarily in Injectables, Insulin, MABs, and GLP-1 projects aligned with guidance. No explicit plans for fresh equity financing were discussed during the

IN US

Sale is live|00:00:00left today

ERIS Lifesciences LtdQ4 FY27Pharmaceuticals & Biotechnology

ERIS Lifesciences Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,461P/E: 42.8Market Cap: ₹19.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Domestic Branded Formulations (DBF) business expects 12% revenue growth for FY26, with Q3 showing 10% growth and 13-14% growth expected for the full year excluding non-core brands.
→DBF segment targets a 37% operating margin this year and 39%+ EBITDA margin next year.
→Significant market share gains in the RHI insulin cartridge segment: from 8% at acquisition to 25-26% by Dec-Jan, with further growth expected in the RHI plus Glargine segment over the next 3 years.
→International business delivered 45% revenue growth in Q3, with strong visibility for FY27 revenue between INR 550-600 crores.
→CDMO revenue expected to grow, with INR 125-160 crore anticipated next year and full commercialization of a INR 1,000 crore order book over three years.
→Launch of GLP-1 products (Semaglutide) expected to drive growth, with initial margin pressure but overall positive top-line impact.
→Insulin production ramp-up from Bhopal expected to enhance margins and volumes.
→Overall, FY27 and beyond are seen as breakout years, especially driven by international markets and new product launches.

Margin guidance

Category 3

→Eris Lifesciences forecasts 12% revenue growth in Domestic Branded Formulations (DBF) for FY26 with a 37% operating margin.
→Consolidated Q3 revenue grew 11% YoY to INR 807 crore with a consolidated margin expansion of 80 bps to 36% YTD.
→Profit After Tax (PAT) growth from operations was about 39% in Q3.
→International business is expected to reach INR 550-600 crore in revenue in FY27, marking a breakout year.
→The CDMO revenue is expected to be INR 125-160 crore next year, with full commercialization of the INR 1,000 crore order book spread over three years.
→FY26 EBITDA margin for DBF expected above 39%.
→Operating costs from manufacturing initiatives (~INR 60-90 crore annually) likely to break even next year.
→Gross margin pressure from initial GLP-1 launch expected but to be offset by DBF scale and upcoming insulin production.
→EPS growth: Q3 EPS INR 9, 9M EPS INR 28, with nearly 40% PAT growth YoY.

3 more insights locked — sign up free to unlock

Fundraise plans

→No specific mention of new fundraising through debt or equity in the current quarter.
→The company disclosed that CapEx guidance for the next 3 years remains unchanged at around INR 750 crore.
→They are focused on managing and reducing net debt to reach a target net debt to EBITDA ratio of 1.5x by the end of the calendar year.
→Debt repayment schedules remain consistent with the previous quarter; no changes reported.
→Capital investments continue primarily in Injectables, Insulin, MABs, and GLP-1 projects aligned with guidance.
→No explicit plans for fresh equity financing were discussed during the call.

Order book

→The current CDMO order book stands at an annualized size of INR 1,000 crore as of Q3FY26.
→This INR 1,000 crore order book is additional to the existing base business, primarily from the Swiss facility.
→The full commercialization and execution of this INR 1,000 crore order book is expected to take about three years.
→For the next year (FY27), the company expects CDMO revenues of INR 125-160 crore.
→The company has strong visibility of FY27 as a breakout year for international revenues, targeting INR 550-600 crore.
→Capacity-wise, Swiss operates two facilities currently, sufficient for FY27; a third larger facility is expected by FY28.
→The company may explore new CMO opportunities such as Semaglutide generics depending on approval timelines.

Capex plans

Yes

→Ongoing capital investments are focused on Injectables, Insulin, Monoclonal Antibodies (MABs), and GLP-1 segments, continuing as per guidance (Page 16).
→CapEx for FY26 Q3 was about INR 80 crore, with nine-month CapEx around INR 200 crore, targeting Insulin, GLP-1, and Injectable projects (Page 5).
→The 3-year CapEx guidance remains around INR 200-250 crore per annum, totaling approximately INR 750 crore for FY26-FY28 (Pages 5 and 6).
→Investment front-loaded to capitalize on strategic opportunities in Injectable Insulin and GLP segments (Page 6).
→New manufacturing Unit 3 at Swiss facility to be commissioned in FY28, significantly expanding capacity for CDMO business (Page 15).
→Strategic expansion planned with strong growth visibility in international business, including CDMO clients in regulated markets expected to contribute INR 550-600 crore in FY27 (Page 16).

How does ERIS Lifesciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1ERIS Lifesciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like ERIS Lifesciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio